For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-human-papillomavirus-infection-drug-market-and-clinical-trials-insight-2023.php
Table of Contents
1. Introduction to Human Papillomavirus Infection
1.1 Overview
1.2 Pathogenicity and Diversity of Human Papillomavirus
1.2.1 Alpha Papillomaviruses
1.2.2 Beta Papillomaviruses
1.2.3 Gamma Papillomaviruses
2. Pathophysiology of Human Papillomavirus
2.1 Life Cycle of Human Papillomavirus
2.1.1 Primary Infection of Epidermis Layer
2.1.2 Genome Maintenance
2.1.3 Proliferative Phase
2.1.4 Viral Genome Amplification
2.1.5 Virus Assembly and Release
2.2 Molecular Mechanism of Human Papillomavirus to Induce Disease
3. Response of Immune System Against Human Papillomavirus
3.1 Innate Immunity
3.2 Adaptive Immunity
4. Clinical Management Strategies Against Human Papillomavirus Infection
4.1 Vaccination Approach for Human Papillomavirus
4.2 Therapeutic Drugs Targets
4.2.1 Interferon
4.2.2 RNA Interference based Therapies
4.2.3 Natural or Herbal Derivatives
5. Emerging Therapies for Treatment of Infection
5.1 Live Vector based Vaccines
5.2 Protein or Peptide based Vaccines
5.3 Nucleic Acid based Vaccines
5.4 Whole Cell based Vaccines
6. Approved Drugs for Treating Human Papillomavirus Infection: Clinical, Drug Class and Patent Insight
6.1 Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil and Silgard)
6.2 Interferon alpha-2b (Intron A, Viraferon and Virtron)
6.3 Tretinoin (Acnisdin Retinoico, Avita, Dermojuventus, Loderm Retinoico, Retirides, Vesanoid, Vitamin-A Acid and Vitanol)
6.4 Imiquimod (Aldara, Beselna Cream 5%, Vyloma and Zyclara)
6.5 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix)
6.6 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
6.7 Interferon-alpha-n3 (Alferon LDO, Alferon N, Alferon N Gel, Alferon N Injection, Alferon N LDO, Altemol and Naturaferon)
6.8 Polyphenon E (Polyphenon E and Veregen)
6.9 Interferon Gamma Biosimilar (Ingaron)
7. Global Human Papillomavirus Infection Market Analysis
7.1 Introduction to Infectious Disease Market
7.2 Global Human Papillomavirus Market Analysis
8. Global Human Papillomavirus Infection Drug Market Dynamics
8.1 Favorable Parameters
8.2 Challenges to Market Growth
9. Global Human Papillomavirus Infection Drug Market Future Perspective
10. Global Human papillomavirus Infections Drug Clinical Pipeline by Company and Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III
11. Competitive Landscape
11.1 3M Pharmaceuticals
11.2 Aclaris Therapeutics
11.3 Mylan Pharmaceuticals
11.4 Biogen Idec
11.5 Cutanea Life Sciences
11.6 Hemispherx
11.7 Inovio Pharmaceuticals
11.8 ISA Pharmaceuticals
11.9 Lees Pharmaceutical Holdings
11.10 MedImmune
11.11 Merck
11.12 Nielsen BioSciences
11.13 Novan
Figure 1-1: Structural Components of Viral Particles
Figure 1-2: Fundamental Constituents of Human Papillomavirus
Figure 1-3: Classification and Diversity of Human Papillomavirus
Figure 2-1: Life Cycle of Human Papillomavirus to Cause the Infection
Figure 2-2: Multistep Model of Cancer Development by Human Papillomavirus
Figure 3-1: HPV Infection Model and Activation of Innate Immune Response
Figure 3-2: Adaptive Immune Response to Human Papillomavirus Infection
Figure 4-1: Clinical Management Strategies for Treating Human Papillomavirus Infections
Figure 4-2: HPV L1 VLP Vaccine Mechanism of Action
Figure 4-3: Response of Interferons with Human Papillomavirus
Figure 7-1: Global andndash; Infectious Disease Diagnostic Market Growth Estimation (US$ Million), 2016-2023
Figure 7-2: Global Infectious Therapeutics Market Growth (US$ Billion), 2016-2023
Figure 7-3: Global Viral Infections Market Growth Estimation (US$ Billion), 2016-2023
Figure 7-4: Global – HPV Therapeutics Market (US$ Billion), 2016-2023
Figure 7-5: Global – Human Papillomavirus Infection Drug Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global – Human Papillomavirus Infection Drug Pipeline by Phase (Number), 2017 till 2023
Figure 7-7: Global andndash; Active and Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (%), 2017 till 2023
Figure 7-8: Global andndash; Active and Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (Number), 2017 till 2023
Figure 8-1: Global – Favorable Parameters to Human Papilloma Virus Market Growth
Figure 8-2: Global – Challenges to Human Papilloma Virus Infection Development
List of Tables
Table 3-1: List of RNA Studies Targeting HPV E6 and E7
Table 3-2: Molecular Targeting HPV and Host Cellular Factors Interaction Using Natural and Herbal Derivatives
